1. Inhaled nitric oxide: an sGC-dependent IOP lowering agent
- Author
-
Warren M. Zapol, Peter Brouckaert, Sara Vandenwijngaert, Wolfgang S. Lieb, Ana C. Dordea, Emmanuel S. Buys, Robert E. Tainsh, and Stefan Münster
- Subjects
Pharmacology ,Intraocular pressure ,genetic structures ,business.industry ,Guanosine ,Vasodilation ,medicine.disease ,Pulmonary hypertension ,eye diseases ,Nitric oxide ,chemistry.chemical_compound ,Isoflurane ,chemistry ,Meeting Abstract ,medicine ,Breathing ,Pharmacology (medical) ,business ,medicine.drug ,Guanylate cyclase - Abstract
Background The nitric oxide (NO)-soluble guanylate cyclase (sGC)cyclic guanosine 3’5’-monophosphate (cGMP) pathway regulates intraocular pressure (IOP). Preclinical and clincial studies have demonstrated the ability of NO-donor compounds to lower IOP (e.g. VESNEO). The use of inhaled NO gas (iNO), a specific pulmonary but not systemic vasodilator, is an approved therapy for pulmonary hypertension and is under development as a treatment for other cardiovascular diseases (e.g. for myocardial ischemia, the NOMI trial). We hypothesized that breathing NO lowers IOP in an sGC-dependent manner.
- Published
- 2015